Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV‐1 resistance mutation.
Saved in:
| Title: | Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV‐1 resistance mutation. |
|---|---|
| Authors: | Stirrup, OT1 oliver.stirrup@ucl.ac.uk, Asboe, D2, Pozniak, A2,3, Sabin, CA1, Gilson, R1,4, Mackie, NE5, Tostevin, A1, Hill, T1, Dunn, DT1, Chadwick, David, Churchill, Duncan, Clark, Duncan, Collins, Simon, Delpech, Valerie, Douthwaite, Samuel, Fearnhill, Esther, Porter, Kholoud, Fraser, Christophe, Geretti, Anna Maria, Gunson, Rory |
| Source: | HIV Medicine. May2020, Vol. 21 Issue 5, p309-321. 13p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
